monomethylpropion has been researched along with Parkinsonian Disorders in 11 studies
monomethylpropion: metabolite of dimethylpropion; structure given in first source
2-methylamino-1-phenylpropan-1-one : An aromatic ketone that is propiophenone in which the hydrogen alpha- to the keto group has been replaced by a methylamino group.
methcathinone : A racemate comprising equal amounts of (R)- and (S)-methcathinone.
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The patients had a parkinsonian syndrome with symmetrical bradykinesia, dystonias, and postural, gait and speech impairment, with moderate restrictions in activities of daily living." | 1.56 | Cognitive profile of patients with manganese-methcathinone encephalopathy. ( Ennok, M; Haldre, S; Sikk, K; Taba, P, 2020) |
| "A number of cases of severe parkinsonism-dystonia have been recognized and reported following the illicit use of ephedrone prepared from pseudoephedrine and potassium permanganate." | 1.56 | Neuropathological Findings in Ephedrone Encephalopathy. ( Dziewulska, D; Fedoryshyn, L; Holton, JL; Kuzyk, P; Lees, AJ; Matviyenko, Y; Sanotsky, Y; Selikhova, M; Semeryak, O, 2020) |
| "A permanent Parkinsonian syndrome occurs in intravenous abusers of the designer psychostimulant methcathinone (ephedrone)." | 1.43 | Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome. ( Donaghy, M; Ilves, P; Johansen-Berg, H; Juurmaa, J; Menke, RA; Müürsepp, A; Nigul, M; Stagg, CJ; Stepens, A; Taba, P; Tomberg, T; Vila, P, 2016) |
| "In ephedrone-induced parkinsonism a prominent mixed hyperkinetic-hypokinetic dysarthria occurs that appears related to marked dystonia and bradykinesia and probably reflects manganese induced toxic and neurodegenerative damage to the globus pallidus internus and substantia nigra." | 1.40 | A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse. ( Bonnet, C; Brožová, H; Janelidze, M; Khatiashvili, I; Megrelishvili, M; Okujava, M; Rusz, J; Růžička, E; Sekhniashvili, M; Tolosa, E, 2014) |
| "Patients with ephedrone parkinsonism (EP) show a complex, rapidly progressive, irreversible, and levodopa non-responsive parkinsonian and dystonic syndrome due to manganese intoxication." | 1.40 | Eye movements in ephedrone-induced parkinsonism. ( Bergquist, J; Bonnet, C; Botchorishvili, N; Brožová, H; Fiala, O; Gaymard, B; Hanuška, J; Janelidze, M; Jech, R; Kapianidze, M; Khatiashvili, I; Matoušková, O; Megrelishvili, M; Mikeladze, N; Nikolai, T; Okujava, M; Rivaud-Péchoux, S; Roth, J; Rusz, J; Růžička, E; Serranová, T; Sieger, T, 2014) |
| "A new form of presumed manganese poisoning has been reported in drug-addicted persons from Russia, Ukraine, and Estonia who have intravenously injected self-prepared methcathinone hydrochloride (Ephedrone)." | 1.34 | Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. ( de Bie, RM; Gladstone, RM; Ko, JH; Lang, AE; Strafella, AP, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 6 (54.55) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Ennok, M | 1 |
| Sikk, K | 3 |
| Haldre, S | 3 |
| Taba, P | 4 |
| Sanotsky, Y | 2 |
| Selikhova, M | 2 |
| Fedoryshyn, L | 2 |
| Kuzyk, P | 1 |
| Matviyenko, Y | 2 |
| Semeryak, O | 1 |
| Dziewulska, D | 1 |
| Holton, JL | 1 |
| Lees, AJ | 1 |
| Rusz, J | 2 |
| Megrelishvili, M | 2 |
| Bonnet, C | 2 |
| Okujava, M | 2 |
| Brožová, H | 2 |
| Khatiashvili, I | 2 |
| Sekhniashvili, M | 1 |
| Janelidze, M | 2 |
| Tolosa, E | 1 |
| Růžička, E | 2 |
| Koksal, A | 1 |
| Keskinkılıc, C | 1 |
| Sozmen, MV | 1 |
| Dirican, AC | 1 |
| Aysal, F | 1 |
| Altunkaynak, Y | 1 |
| Baybas, S | 1 |
| Golasik, M | 1 |
| Wodowski, G | 1 |
| Gomółka, E | 1 |
| Herman, M | 1 |
| Piekoszewski, W | 1 |
| Sieger, T | 1 |
| Matoušková, O | 1 |
| Nikolai, T | 1 |
| Hanuška, J | 1 |
| Kapianidze, M | 1 |
| Mikeladze, N | 1 |
| Botchorishvili, N | 1 |
| Serranová, T | 1 |
| Fiala, O | 1 |
| Roth, J | 1 |
| Bergquist, J | 3 |
| Jech, R | 1 |
| Rivaud-Péchoux, S | 1 |
| Gaymard, B | 1 |
| Juurmaa, J | 1 |
| Menke, RA | 1 |
| Vila, P | 1 |
| Müürsepp, A | 1 |
| Tomberg, T | 1 |
| Ilves, P | 1 |
| Nigul, M | 1 |
| Johansen-Berg, H | 1 |
| Donaghy, M | 1 |
| Stagg, CJ | 1 |
| Stepens, A | 1 |
| Komnatska, I | 1 |
| Kyrylchuk, M | 1 |
| Krolicki, L | 1 |
| Friedman, A | 1 |
| Taylor, A | 1 |
| Jäger, HR | 1 |
| Lees, A | 1 |
| Nyholm, D | 2 |
| Askmark, H | 1 |
| Danfors, T | 1 |
| Sörensen, J | 1 |
| Thurfjell, L | 1 |
| Raininko, R | 1 |
| Eriksson, R | 1 |
| Flink, R | 1 |
| Färnstrand, C | 1 |
| Aquilonius, SM | 2 |
| Zjablov, G | 1 |
| Asser, T | 1 |
| de Bie, RM | 1 |
| Gladstone, RM | 1 |
| Strafella, AP | 1 |
| Ko, JH | 1 |
| Lang, AE | 1 |
11 other studies available for monomethylpropion and Parkinsonian Disorders
| Article | Year |
|---|---|
Cognitive profile of patients with manganese-methcathinone encephalopathy.
Topics: Adolescent; Adult; Brain Diseases; Cognition; Cognitive Dysfunction; Female; Humans; Male; Manganese | 2020 |
Neuropathological Findings in Ephedrone Encephalopathy.
Topics: Adult; Brain Diseases; Female; Humans; Manganese Poisoning; Parkinsonian Disorders; Propiophenones | 2020 |
A distinct variant of mixed dysarthria reflects parkinsonism and dystonia due to ephedrone abuse.
Topics: Acoustics; Adult; Analysis of Variance; Antiparkinson Agents; Dysarthria; Dystonia; Humans; Magnetic | 2014 |
Evaluation of cognitive characteristics of patients developing manifestations of parkinsonism secondary to long-term ephedrone use.
Topics: Adult; Cognition Disorders; Humans; Male; Manganese Poisoning; Neuropsychological Tests; Parkinsonia | 2014 |
Urine as a material for evaluation of exposure to manganese in methcathinone users.
Topics: Humans; Manganese; Parkinsonian Disorders; Propiophenones; Spectrophotometry, Atomic | 2014 |
Eye movements in ephedrone-induced parkinsonism.
Topics: Adult; Basal Ganglia; Brain; Eye Movements; Female; Humans; Male; Manganese; Middle Aged; Parkinsoni | 2014 |
Grey matter abnormalities in methcathinone abusers with a Parkinsonian syndrome.
Topics: Adult; Atrophy; Brain; Case-Control Studies; Female; Gray Matter; Humans; Magnetic Resonance Imaging | 2016 |
Parkinsonism and dystonia caused by the illicit use of ephedrone--a longitudinal study.
Topics: Adolescent; Adult; Brain; Dystonic Disorders; Humans; Illicit Drugs; Longitudinal Studies; Magnetic | 2008 |
Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure.
Topics: Adult; Basal Ganglia Diseases; Corpus Striatum; Female; Humans; Magnetic Resonance Imaging; Male; Ma | 2010 |
Irreversible motor impairment in young addicts--ephedrone, manganism or both?
Topics: Adult; Brain; Central Nervous System Stimulants; Disability Evaluation; Disease Progression; Dyskine | 2007 |
Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse.
Topics: Adult; Brain Diseases; Humans; Magnetic Resonance Imaging; Male; Manganese Poisoning; Parkinsonian D | 2007 |